M
Mark I. Greene
Researcher at University of Pennsylvania
Publications - 548
Citations - 29790
Mark I. Greene is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Antigen & Immune system. The author has an hindex of 88, co-authored 532 publications receiving 28626 citations. Previous affiliations of Mark I. Greene include University of Manitoba & Massachusetts Institute of Technology.
Papers
More filters
Journal ArticleDOI
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen.
Alan L. Schechter,David F. Stern,Lalitha Vaidyanathan,Stuart J. Decker,Jeffrey A. Drebin,Mark I. Greene,Robert A. Weinberg +6 more
TL;DR: A series of rat neuro/glioblastomas all contain the same transforming gene (neu) which induces synthesis of a tumour antigen of relative molecular mass (Mr) 185,000 (p185), which is serologically related to the epidermal growth factor (EGF) receptor.
Journal ArticleDOI
Deacetylase inhibition promotes the generation and function of regulatory T cells
Ran Tao,Edwin F. de Zoeten,Engin Ozkaynak,Chunxia Chen,Liqing Wang,Paige M. Porrett,Bin Li,Laurence A. Turka,Eric N. Olson,Mark I. Greene,Andrew D. Wells,Wayne W. Hancock +11 more
TL;DR: Administration of an HDAC inhibitor (HDACi) in vivo increased Foxp3 gene expression, as well as the production and suppressive function of regulatory T cells (Treg cells), and HDAC9 proved particularly important in regulatingFoxp3-dependent suppression.
Journal ArticleDOI
Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer
Yukiko Tone,Keiji Furuuchi,Yoshitsugu Kojima,Mark L. Tykocinski,Mark I. Greene,Masahide Tone +5 more
TL;DR: A model system is generated for analyzing Foxp3 induction and an enhancer element is identified in this gene, which explains many of the effects of transforming growth factor-β on the function ofFoxp3+ Treg cells.
Journal ArticleDOI
ErbB receptors: from oncogenes to targeted cancer therapies
Hongtao Zhang,Alan Berezov,Qiang Wang,Geng Zhang,Jeffrey A. Drebin,Ramachandran Murali,Mark I. Greene +6 more
TL;DR: Current therapy has not yet been optimized, allowing for opportunities for optimization of the next generation of targeted therapy, particularly with regards to inhibiting heteromeric ErbB family receptor complexes.
Journal ArticleDOI
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
Sae Gwang Park,Zhujun Jiang,Eric D. Mortenson,Liufu Deng,Olga Radkevich-Brown,Xuanming Yang,Husain Sattar,Yang Wang,Nicholas K. Brown,Mark I. Greene,Yang Liu,Jie Tang,Shengdian Wang,Yang Xin Fu,Yang Xin Fu +14 more
TL;DR: It is demonstrated that the mechanisms of tumor regression by anti-HER2/neu antibody therapy also require the adaptive immune response, and the addition of chemotherapeutic drugs, although capable of enhancing the reduction of tumor burden, could abrogate antibody-initiated immunity leading to decreased resistance to rechallenge or earlier relapse.